Particularly, using this technology, it was reported that the generation of CD33-specific CAR-NK cells combined with CRISPR-Cas9-based gene disruption of the NKG2A-encoding KLRC1 gene resulted in the generation of CAR-NK cells with enhanced cytotoxicity against CD33-positive AML blasts [49]. The gene discussed is KLRC1; the disease is acute myeloid leukemia.